Business Context and Reporting Period
This Form 8-K Current Report for cbdMD, Inc. covers events occurring on March 29, 2024, specifically the company's 2024 Annual Meeting of Shareholders and subsequent Board of Directors actions. The filing details the election of directors, ratification of auditors, executive compensation votes, and significant changes to the company's executive leadership and board structure.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Corporate Actions
Annual Meeting Results
- Quorum: 1,053,909 shares of common stock (34.6%) and 3,465,131 shares of Series A Preferred Stock (69.3%) were represented.
- Approved Proposals:
- Proposal 1: Election of four directors (Bakari Sellers, William F. Raines, III, Scott G. Stephen, Dr. Sybil Swift).
- Proposal 2: Ratification of Cherry Bekaert LLP as independent auditors.
- Proposal 3: Advisory vote on executive compensation frequency (majority voted for "One" year).
- Proposal 4: Advisory approval of fiscal year 2024 executive compensation.
- Proposal 6: Approval to issue common stock representing more than 19.9% of outstanding shares upon conversion of convertible notes issued to five institutional investors.
- Rejected Proposal:
- Proposal 5: Amendment to the Certificate of Designation for Series A Preferred Stock to provide for automatic conversion into common stock was not approved. While common stockholders voted largely in favor, Series A holders voted against (1,674,962 against vs. 1,790,169 for).
Leadership and Board Changes
- Executive Appointments:
- T. Ronan Kennedy appointed Chief Executive Officer and Chief Financial Officer.
- Bradley Whitford (formerly VP of Finance) appointed Chief Accounting Officer, Treasurer, and Secretary. His annual base salary is set at $200,000.
- Board Appointments:
- Scott Stephen appointed Chairman of the Board.
- Committee Assignments: William F. Raines, III (Audit Committee Chair); Bakari Sellers (Compensation, Corporate Governance and Nominating Committee Chair).
- Director Compensation: Board members received cash fees consistent with the prior year, plus grants of 4,000 Restricted Stock Units (vesting quarterly) and options for 2,000 shares (vesting immediately).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosure of the failed Proposal 5 regarding Series A conversion. The rejection of the automatic conversion amendment for Series A Preferred Stock indicates a divergence in interest between common and preferred shareholders regarding capital structure changes.
Investor Verification Checklist
- Verify the terms of the convertible notes approved in Proposal 6 and the potential dilution impact of issuing shares representing over 19.9% of outstanding common stock.
- Review the Series A Preferred Stock designation to understand the implications of the failed automatic conversion amendment (Proposal 5).
- Confirm the compensation structure for the newly appointed CEO/CFO (T. Ronan Kennedy) and CAO (Bradley Whitford) in subsequent filings, as only Whitford's base salary is disclosed here.
- Monitor the vesting schedule for the new director equity grants (RSUs and options) to assess future dilution.